BioSyent Pharma Inc. news
BioSyent Inc. ("BioSyent", TSX Venture: RX) released today its financial results for the three months ended March 31, 2022. Key highlights include:
- First quarter (Q1) 2022 Net Revenues of $7,037,411 decreased by 5% versus Q1 2021
- Q1 2022 Net Revenues from continuing brands (excluding discontinued Aguettant System® and Cysview® brands) decreased by 0% versus Q1 2021
- Q1 2022 Canadian Pharmaceutical Net Revenues of $6,318,884 increased by 1% versus Q1 2
MISSISSAUGA, ONTARIO (May 10, 2022) BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting
its financial results for the three months ended March 31, 2022 on Wednesday, May 18, 2022 at 8:00am ET. A
presentation on the Company’s first quarter 2022 results by René Goehrum, BioSyent President and CEO, will also be
available on the Company’s website on the date of release.
About BioSyent Inc.<
MISSISSAUGA, ONTARIO (May 2,2022) BioSyent Inc. ("BioSyent", TSX Venture: RX) is pleased to announce that for the seventh consecutive year, FeraMAX® is the #1 recommended iron supplement brand in Canada based on a national survey of Canadian pharmacists and physicians.1
This annual survey was conducted by EnsemblelQ, Research, Insights and Innovation team and the following publications and websites: Pharmacy Practice + Business, The Medical Post, Profession Sante, CanadianHealthca